nach oben

Acta Neurologica Belgica

Erschienen in:

01.12.2012 | Review Article

Vitamin D and multiple sclerosis: a critical review and recommendations on treatment

verfasst von: Alireza Faridar, Ghazaleh Eskandari, Mohammad Ali Sahraian, Alireza Minagar, Amirreza Azimi

Erschienen in: Acta Neurologica Belgica | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is an immune-mediated and degenerative disease of nervous system, which affects mostly young adults. Vitamin D deficiency is a well-known environmental risk factor for MS and is considerable in terms of immediate clinical implications. In addition to its classical action on regulation of bone homeostasis, vitamin D may have a potent impact on cytokine profiles and neuro-inflammation. Given the immunomodulatory effects of vitamin D and its high rate of deficiency in MS patients, prescribing vitamin D is a remarkable issue in MS. The results from several experimental and clinical studies indicate that vitamin D supplementation may ameliorate the inflammation during the relapse phase and attenuate disease progression. We present the experimental and clinical studies, which assessed the effects of vitamin D on the pathophysiology, prevalence and management of MS. The authors also discuss current recommendations on prescription of this vitamin to MS patients.

Munger K, Levin L, Hollis B, Howard N, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832PubMedCrossRef

Giovannoni G (1997) The immunopathogenesis of multiple sclerosis. Baillière’s Clin Neurol 6(3):387

Ascherio A, Munger K (eds) (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Thieme-Stratton Inc., New York

Ramagopalan SV, Ebers GC (2008) Genes for multiple sclerosis. The lancet 371(9609):283–285. doi:10.1016/S0140-6736(08)60145-2

Irizar H, Muñoz-Culla M, Zuriarran O, Goyenechea E, Castillo-Triviño T, Prada A et al (2011) HLA-DRB1* 15:01 and multiple sclerosis: a female association? Multiple Scler J

Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, Scherer S, Opelz G et al (1998) HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. Eur J Immunogenet 25(4):297–301PubMedCrossRef

Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214–219PubMedCrossRef

Handel A, Giovannoni G, Ebers G, Ramagopalan S (2010) Environmental factors and their timing in adult-onset multiple sclerosis. Nature Rev Neurol 6(3):156–166

Chaudhuri A (2005) Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses 64(3):608–618PubMedCrossRef

10.

Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(6):1678SPubMed

11.

Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137PubMedCrossRef

12.

Cutolo M (2009) Vitamin D and autoimmune rheumatic diseases. Rheumatology 48(3):210PubMedCrossRef

13.

Holick MF, Krane SM, Potts J (1998) Calcium, phosphorus, and bone metabolism: calcium-regulating hormones. Harrisons Princ Intern Med:2214–2226

14.

Heaney RP (2008) Vitamin D criteria for safety and efficacy. Nutr Rev 66:S178–S181PubMedCrossRef

15.

Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89(05):552–572PubMedCrossRef

16.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117(4):503PubMedCrossRef

17.

Hollis BW (2004) Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89(7):3149PubMedCrossRef

18.

Ross AC, Manson JAE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53PubMedCrossRef

19.

Staud R (2005) Vitamin D: more than just affecting calcium and bone. Curr Rheumatol Rep 7(5):356–364PubMedCrossRef

20.

Phinney KW (2008) Development of a standard reference material for vitamin D in serum. Am J Clin Nutr 88(2):511SPubMed

21.

Rafique I, Frederiksen J A (2010) complete literature survey: vitamin D and multiple sclerosis–what is clearly evident? Eur Neurol J 2(2):113–120

22.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(7):1911PubMedCrossRef

23.

Hanwell HEC, Banwell B (2011) Assessment of evidence for a protective role of vitamin D in multiple sclerosis. Biochim et Biophys Acta (BBA)-Mol Basis Dis 1812(2):202–212

24.

Penna G, Adorini L (2000) 1, 25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164(5):2405PubMed

25.

Ponsonby AL, Lucas R, Mei IAF (2005) UVR, vitamin D and three autoimmune diseases—multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol 81(6):1267–1275PubMedCrossRef

26.

Lemire JM (1995) Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53(1–6):599–602PubMedCrossRef

27.

van Etten E, Gysemans C, Branisteanu D, Verstuyf A, Bouillon R, Overbergh L et al (2007) Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol 103(3–5):546–551PubMedCrossRef

28.

van Halteren AGS, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1 [alpha], 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23(3):233–239PubMedCrossRef

29.

Mark BL, Carson JAS (2006) Vitamin D and autoimmune disease–implications for practice from the multiple sclerosis literature. J Am Diet Assoc 106(3):418–424PubMedCrossRef

30.

Pierrot-Deseilligny C (2009) Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 256(9):1468–1479PubMedCrossRef

31.

Correale J, Ysrraelit M, Gaitán M (2009) Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132(5):1146PubMedCrossRef

32.

Knippenberg S, Smolders J, Thewissen M, Peelen E, Tervaert JWC, Hupperts R et al (2011) Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Multiple Scler J

33.

Smolders J, Peelen E, Thewissen M, Tervaert JWC, Menheere P, Hupperts R et al (2010) Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 5(12):e15235PubMedCrossRef

34.

Mahon B, Gordon S, Cruz J, Cosman F, Cantorna M (2003) Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134(1–2):128–132PubMedCrossRef

35.

Ebers G, Sadovnick A (1993) The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 12(1):1–5PubMedCrossRef

36.

Acheson E, Bachrach C, Wright F (1960) Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand 35(S147):132–147

37.

Smolders J (2011) Vitamin D and multiple sclerosis: correlation, causality, and controversy

38.

Poppe AY, Wolfson C, Zhu B (2008) Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci 35(5):593–601PubMed

39.

Grønlie SA, Myrvoll E, Hansen G, Grønning M, Mellgren SI (2000) Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol 247(2):129–133

40.

Fernandes de Abreu DA, Landel V, Féron F (2011) Seasonal, gestational and postnatal influences on multiple sclerosis: the beneficial role of a vitamin D supplementation during early life. J Neurol Sci 311(1–2):64–68PubMedCrossRef

41.

Van der Mei I, Ponsonby A, Dwyer T, Blizzard L, Simmons R, Taylor B et al (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327(7410):316PubMedCrossRef

42.

Kampman M, Wilsgaard T, Mellgren S (2007) Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254(4):471–477PubMedCrossRef

43.

Noonan F, Bucana C, Sauder D, De Fabo E (1984) Mechanism of systemic immune suppression by UV irradiation in vivo. II. The UV effects on number and morphology of epidermal Langerhans cells and the UV-induced suppression of contact hypersensitivity have different wavelength dependencies. J Immunol 132(5):2408PubMed

44.

Hanneman K, Cooper K, Baron E (2006) Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin 24(1):19PubMedCrossRef

45.

Beretich B, Beretich T (2009) Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Multiple Scler 15(8):891CrossRef

46.

Mirzaei F, Michels KB, Munger K, O’Reilly E, Chitnis T, Forman MR et al Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol 70(1):30–40

47.

Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Scler 11(3):266CrossRef

48.

Munger K, Zhang S, O’Reilly E, Hernan M, Olek M, Willett W et al (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1):60PubMedCrossRef

49.

Munger K, Chitnis T, Frazier A, Giovannucci E, Spiegelman D, Ascherio A (2011) Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 258(3):479–485PubMedCrossRef

50.

Simon K, Munger K (2010) Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Multiple Scler 16(2):133CrossRef

51.

Wüthrich R, Rieder H (1970) The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 3(5):257PubMedCrossRef

52.

Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Mesaros D et al (2008) Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 31(4):271–279PubMedCrossRef

53.

Embry A, Snowdon L, Vieth R (2000) Vitamin D and seasonal fluctuations of gadolinium enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 48(2):271–272PubMedCrossRef

54.

Cantorna MT, Hayes CE, DeLuca HF (1996) 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93(15):7861PubMedCrossRef

55.

Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA et al (2004) Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics 18(2):141–151PubMedCrossRef

56.

Orton S, Morris A, Herrera B, Ramagopalan S, Lincoln M, Chao M et al (2008) Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 88(2):441PubMed

57.

Smolders J, Damoiseaux J, Menheere P, Tervaert J, Hupperts R (2009) Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis. Ann NY Acad Sci 1173(1):515–520PubMedCrossRef

58.

Mowry E, Krupp L, Milazzo M, Chabas D, Strober J, Belman A et al (2010) Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67(5):618–624PubMed

59.

Goldberg P, Fleming M, Picard E (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 21(2):193–200PubMedCrossRef

60.

Wingerchuk D, Lesaux J, Rice G, Kremenchutzky M, Ebers G (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing–remitting multiple sclerosis. Br Med J 76(9):1294

61.

Burton J, Kimball S, Vieth R, Bar-Or A, Dosch H, Cheung R et al (2010) A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74(23):1852PubMedCrossRef

62.

Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L (2012) Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Scler [Epub ahead of print]

63.

Soilu-Hänninen M, Ãivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M et al (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83(5):565–571PubMedCrossRef

64.

van Etten E, Gysemans C, Branisteanu DD, Verstuyf A, Bouillon R, Overbergh L et al (2007) Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol 103(3):546–551PubMedCrossRef

65.

Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44(9):1687PubMedCrossRef

66.

Hiremath G, Cettomai D, Baynes M, Ratchford J, Newsome S, Harrison D et al (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Multiple Scler 15(6):735CrossRef

67.

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53–58PubMedCrossRef

68.

Pierrot-Deseilligny C, Souberbielle JC (2011) Widespread vitamin D insufficiency: a new challenge for primary prevention, with particular reference to multiple sclerosis. La Press Med

69.

Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95(2):471PubMedCrossRef

70.

Haroon M, Regan MJ (2010) Vitamin D deficiency: the time to ignore it has passed. Int J Rheum Dis 13(4):318–323PubMedCrossRef

71.

Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16(7):713–716PubMedCrossRef

72.

Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna J, Lilius E, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79(2):152PubMedCrossRef

73.

Cantorna M, Mahon B (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 229(11):1136–1142

74.

Kimball S, Ursell M, O’Connor P, Vieth R (2007) Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 86(3):645PubMed

75.

Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Investig 40(6):627–639CrossRef

Titel: Vitamin D and multiple sclerosis: a critical review and recommendations on treatment
verfasst von: Alireza Faridar
Ghazaleh Eskandari
Mohammad Ali Sahraian
Alireza Minagar
Amirreza Azimi
Publikationsdatum: 01.12.2012
Verlag: Springer Milan
Erschienen in: Acta Neurologica Belgica / Ausgabe 4/2012
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-012-0108-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vitamin D and multiple sclerosis: a critical review and recommendations on treatment

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Difficult differential diagnosis of Unverricht–Lundborg disease with spontaneous kinesogenic myoclonus and movement disorder

Epilepsy and psychiatric problems in a patient with a large intracranial mass

Neurocysticercosis in Western Europe: a re-emerging disease?

Effect of dexamethasone on the frequency of postdural puncture headache after spinal anesthesia for cesarean section: a double-blind randomized clinical trial

Posterior leukoencephalopathy in NARP syndrome

Subdural hematoma in a young woman with an “old” brain

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie